RxDoctor Payments Data

Kameswari Kalluri, MD

Internal Medicine · Munster, INNPI 1700815644

Payments from drug & device makers

$1,315in general payments, 2019–2025

Across 33 payments — averaging $39.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$250
  • Novo Nordisk$137
  • Johnson & Johnson$127
  • Lilly USA, LLC$125
  • Lexicon Pharmaceuticals, Inc.$123
  • Heartflow, Inc.$106
  • plus $448 from 10 others

What the payments were for

  • Food & beverage$1,315100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,315 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$108,146
Medicare patients
181
Services billed
1,543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol58$61,082
JanuviaSitagliptin Phosphate42$54,156
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$46,528
EliquisApixaban37$45,344
OzempicSemaglutide20$27,387
Breo ElliptaFluticasone/Vilanterol15$8,385
Metoprolol Succinate252$3,470
Telmisartan188$2,578
Calcitonin-SalmonCalcitonin,salmon,synthetic28$2,531
Atorvastatin Calcium381$2,233
Levothyroxine Sodium188$1,872
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,826
Duloxetine Hcl114$1,813
Niacin ErNiacin17$1,686
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen92$1,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$96$61,08258 claims
MerckJanuvia$31$54,15642 claims
Novo NordiskOzempic$137$27,38720 claims
AbbVieSynthroid$41$1,15831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →